Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Recent & Breaking News (NDAQ:HALO)

Robbins Arroyo LLP Is Investigating the Officers and Directors of Halozyme Therapeutics, Inc. on Behalf of Shareholders

PR Newswire April 17, 2014

Halozyme Announces Clinical Hold of PEGPH20 Pancreatic Cancer Trial Following Voluntary Halt of Trial by Halozyme

PR Newswire April 9, 2014

Halozyme Announces Preclinical Data Presentations At The Association Of Cancer Research Annual Meeting

PR Newswire April 8, 2014

Halozyme Announces Temporary Halt Of Phase 2 Trial Enrollment And Dosing For PEGPH20

PR Newswire April 4, 2014

Halozyme Announces Appointment Of Oncology Product Team Leader And Other Executive Transitions

PR Newswire April 2, 2014

Halozyme Announces that Consistent 1 Trial Of Hylenex® Recombinant Met Primary Endpoint

PR Newswire March 31, 2014

Halozyme Announces Roche Marketing Authorization For MabThera SC For Patients With Common Forms Of Non-Hodgkin Lymphoma In European Union

PR Newswire March 28, 2014

Halozyme Announces Positive Results From Phase 1/2 Clinical Trial In Cellulite With HTI-501

PR Newswire March 25, 2014

Halozyme Therapeutics To Present At The Barclays 2014 Global Healthcare Conference

PR Newswire March 5, 2014

Halozyme Reports Fourth Quarter And Year End 2013 Financial Results

PR Newswire February 27, 2014

Halozyme Therapeutics To Present At The Cowen And Company 34th Annual Healthcare Conference

PR Newswire February 25, 2014

Halozyme to Host Fourth Quarter and 2013 Year-End Financial Results Conference Call

PR Newswire February 20, 2014

Halozyme Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

PR Newswire February 10, 2014

Halozyme Therapeutics Prices Public Offering Of Common Stock

PR Newswire February 4, 2014

Halozyme Therapeutics Announces Public Offering Of Common Stock

PR Newswire February 3, 2014

Halozyme Announces Positive Opinion From CHMP For European Approval Of Roche's MabThera SC

PR Newswire January 24, 2014

Halozyme Therapeutics Provides an Update on Anticipated Milestones for 2014 at the 32nd Annual J. P. Morgan Healthcare Conference

PR Newswire January 13, 2014

Halozyme Therapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference

PR Newswire January 9, 2014

Halozyme Secures Additional $20 Million Term Loan

PR Newswire January 6, 2014

Intrexon Strengthens Leadership in Company's Rapidly Growing Health Sector

PR Newswire December 17, 2013